LabBook July 25, 2014

Major League Baseball Umpires—and of course Southpaw—visited with patients at Comer Children's Hospital on July 22, 2014. They brought Build-A-Bear stuffed animals and outfits for patients and families. The visit was made possible by Umps Care Charities, a non-profit organized by MLB Umpires, and Bristol-Myers Squibb.

Major League Baseball Umpires—and of course Southpaw—visited with patients at Comer Children’s Hospital on July 22, 2014. They brought Build-A-Bear stuffed animals and outfits for patients and families. The visit was made possible by Umps Care Charities, a non-profit organized by MLB Umpires, and Bristol-Myers Squibb.

This week’s rundown of recent research publications of note from University of Chicago scientists and physicians:

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma: Derek Wainwright, Maciej Lesniak — Oncoimmunology

From the abstract: “Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.”

In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease: including Joseph Maranvillea, Dejan Micicb, Anna Di Rienzoa, Sonia S. Kupfer — Journal of Crohn’s and Colitis

From the abstract: “Glucocorticoids (GCs) are steroid hormones used to induce remission in moderate-to-severe inflammatory bowel disease (IBD). A substantial fraction of patients do not respond to GC treatment and require alternate therapies or surgery. At present, non-response can only be assessed empirically by observing continued disease activity … These results support an important role of bacterial recognition and innate immunity in the etiology of IBD. This assay could be a powerful predictor of clinical response to GCs.”

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer: including Theodore Karrison, Masha Kocherginsky, Jeffrey Mueller, Robyn Egan, Tanguy Seiwert, Victoria Villaflor, Daniel Haraf, and Everett Vokes — Journal of Clinical Oncology

From the abstract: “Induction chemotherapy (IC) before radiotherapy lowers distant failure (DF) rates in locally advanced squamous cell carcinoma of the head and neck (SCCHN). The goal of this phase III trial was to determine whether IC before chemoradiotherapy (CRT) further improves survival compared with CRT alone in patients with N2 or N3 disease … IC did not translate into improved OS compared with CRT alone. However, the study was underpowered because it did not meet the planned accrual target, and OS was higher than predicted in both arms. IC cannot be recommended routinely in patients with N2 or N3 locally advanced SCCHN.”

About Matt Wood (433 Articles)
Matt Wood is a senior science writer for the University of Chicago Medicine and editor of the Science Life blog.
Follow

Get every new post delivered to your Inbox.

Join 2,907 other followers

%d bloggers like this: